<DOC>
	<DOCNO>NCT02042144</DOCNO>
	<brief_summary>This study prospective observational cohort study . The study conduct routine clinical practice setting . It plan enroll 1000 patient metastatic Colorectal Cancer ( mCRC ) previously treat approve treatment metastatic disease decision make physician treat regorafenib accord local health authority approve label . It aim observational cohort study characterize safety effectiveness regorafenib routine clinical practice set . Healthcare resource utilization routine provision care become increasingly important health economics outcomes research perspective . Therefore , another aim observational cohort study capture healthcare resource associate management treatment emergent adverse event real world setting . The primary objective study characterize safety regorafenib use routine clinical practice setting . The secondary objective study ass effectiveness regorafenib routine clinical practice setting measure Overall Survival ( OS ) , Progression Free Survival ( PFS ) Disease control rate ( DCR ) . Health Related Quality Life ( HRQoL ) Data collect applicable country .</brief_summary>
	<brief_title>Safety Effectiveness Regorafenib</brief_title>
	<detailed_description />
	<criteria>Patients diagnose mCRC previously treat , consider candidate , locally approve standard treatment ( ) decision make per investigator 's routine treatment practice prescribe regorafenib . Patients participate investigational program intervention outside routine clinical practice</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Neoplasms , Colorectal</keyword>
</DOC>